Astralis Ltd., partnered with SkyPharma PLC, has initiated a phase I clinical trial in the United States for Psoraxine, a new injectable treatment for moderate psoriasis.
Journal Digest: September 26
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says
Severe Psoriasis Associated With Higher Risk of Heart Disease